true
0001471727
0001471727
2026-07-27
2026-07-27
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K/A
(Amendment
No. 1)
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): July 27, 2026
SRX
Global Inc.
(Exact
name of Registrant as Specified in its Charter)
| Delaware |
|
001-40477 |
|
83-4284557 |
(State
or other Jurisdiction
of
Incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
801
US Highway 1
North
Palm Beach, Florida 33408
(Address
of Principal Executive Offices) (Zip Code)
(Registrant’s
Telephone Number, Including Area Code): (212) 896-1254
N/A
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
Stock, $0.001 par value share |
|
SRXH |
|
NYSE
American |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Explanatory
Note
This
Amendment No.1 (“Amended Report”) amends the Current Report on Form 8-K filed by SRX Global Inc. (the “Company”)
on July 28, 2026 (the “Original Report”) solely to correct a typographical error. The signature block of the Original
Report inadvertently identified Carolina Martinez as the Chief Executive Officer of the Company. Carolina Martinez is the Chief Financial
Officer of the Company.
This Amended Report does not otherwise change or update the disclosures
set forth in the Original Form 8-K.
Item
3.02 Unregistered Sales of Equity Securities.
Private
Placement
Additional
Closing under Securities Purchase Agreement
As
previously announced, on March 16, 2026, SRX Global Inc. (f/k/a SRx Health Solutions, Inc.), a Delaware corporation (the “Company”),
entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain accredited investors named
therein (the “Investors”). Pursuant to the Securities Purchase Agreement, up to 10,000 shares of the Company’s Series
B convertible preferred stock, par value $0.001 per share (the “Series B Preferred Stock”) and accompanying warrants (“Warrants”)
to purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) may be purchased
for an aggregate purchase price of up to $8.0 million in one or more closings.
As
previously announced, on March 16, 2026 at the initial closing, pursuant to the Securities Purchase Agreement, the Company issued and
sold, and certain Investors purchased, in a private placement: 5,660 shares of the Series B Preferred Stock and 22,237,666 Warrants to
purchase shares of Common Stock for aggregate proceeds of approximately $4.528 million, paid in cash.
Pursuant
to the Securities Purchase Agreement, the Investors have the right, severally, subject to the satisfaction of certain conditions, to
require the Company to participate in one or more additional closings for the purchase of up to an aggregate of 4,340 additional shares
of Series B Preferred Stock and Warrants (each such transaction, an “Additional Closing”).
On
July 27, 2026, at an Additional Closing pursuant to the Securities Purchase Agreement, the Company issued and sold, and certain investors
purchased, in a private placement: 4,340 shares of the Series B Preferred Stock and 284,156 Warrants to purchase shares of Common Stock
for aggregate proceeds of approximately $3.472 million, paid in cash. Such number of Warrants is adjusted to reflect the Company’s
previously announced 60-for-1 reverse stock split, which took effect July 2, 2026.
All
such securities will not be registered under the Securities Act in reliance on the exemption from registration provided by Section 4(a)(2)
of the Securities Act and/or Rule 506 of Regulation D promulgated thereunder, or under any state securities laws. The Company relied
on this exemption from registration in entering into the Securities Purchase Agreement and the Company will rely upon this exemption
from registration in issuing such securities based in part on representations made by the investors in the Securities Purchase Agreement.
The securities may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
Neither this Current Report on Form 8-K, nor the exhibits attached hereto, is an offer to sell or the solicitation of an offer to buy
the securities described herein.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| Date: |
July
29, 2026 |
SRX
GLOBAL INC. |
| |
|
|
|
| |
|
By: |
/s/
Carolina Martinez |
| |
|
Name: |
Carolina
Martinez |
| |
|
Title: |
Chief
Financial Officer |